| This study assessed the temporal trends of grade 3/4 adverse event (AE) rates and the associated costs of nivolumab plus cabozantinib combination therapy versus sunitinib monotherapy using individual patient-level data from the pivotal CheckMate 9ER trial. |
| Nivolumab plus cabozantinib was associated with lower all-cause and treatment-related grade 3/4 AE costs compared with sunitinib, despite the higher rate of AEs observed among patients treated with nivolumab plus cabozantinib in the CheckMate 9ER trial. |
| Cost savings appeared to be most prominent within the first month of treatment initiation. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.